Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition
Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.
Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.
Datopotamab deruxtecan demonstrated comparable intracranial activity and safety in pretreated patients with NSCLC with or without brain metastases.
Can metformin use be linked to a lower risk of myeloproliferative neoplasms? Find out from this groundbreaking study.
The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder…
The 29th Congress of the European Hematology Association (EHA) will be held in Madrid, Spain, and online, from June 13-16, 2024. This meeting will bring…
Michael Parry was diagnosed with pancreatic cancer at the age of 59. Fortunately, his disease was detected early – and after surgery and chemotherapy, he…
The 29th Congress of the European Hematology Association (EHA) will be held in Madrid, Spain, and online, from June 13-16, 2024. This meeting will bring…
Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.
In a phase 2 trial, all 42 patients with locally advanced mismatch repair–deficient rectal cancer achieved clinical complete response with dostarlimab.